You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR ONSOLIS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ONSOLIS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00293033 ↗ Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects Completed BioDelivery Sciences International Phase 3 2006-02-01 The purpose of this study is to evaluate the efficacy of BEMA Fentanyl (Onsolis) at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption.
NCT00696137 ↗ Long-term Extension Study of BEMA™ Fentanyl Completed BioDelivery Sciences International Phase 3 2008-06-01 This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.
NCT01158820 ↗ Alternative Sedation During Bronchoscopy Completed Hospira, Inc. Phase 4 2010-06-01 This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure.
NCT01158820 ↗ Alternative Sedation During Bronchoscopy Completed Hospira, now a wholly owned subsidiary of Pfizer Phase 4 2010-06-01 This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure.
NCT01158820 ↗ Alternative Sedation During Bronchoscopy Completed University of Pennsylvania Phase 4 2010-06-01 This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure.
NCT01169025 ↗ Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients Withdrawn University of Utah N/A 2012-09-01 Often, patients transported by aeromedical systems do not receive enough medication to control and relieve their pain. The purpose of this study is to determine if pain treatment with intravenous (IV) ketamine is a better way to treat aeromedical patients' pain than the current treatment practices.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ONSOLIS

Condition Name

Condition Name for ONSOLIS
Intervention Trials
Pain 3
Cancer 2
Respiratory Depression 1
Sedation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ONSOLIS
Intervention Trials
Fibrosis 1
Alpha 1-Antitrypsin Deficiency 1
Respiratory Insufficiency 1
Breakthrough Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ONSOLIS

Trials by Country

Trials by Country for ONSOLIS
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ONSOLIS
Location Trials
Florida 1
Utah 1
Pennsylvania 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ONSOLIS

Clinical Trial Phase

Clinical Trial Phase for ONSOLIS
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ONSOLIS
Clinical Trial Phase Trials
Completed 4
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ONSOLIS

Sponsor Name

Sponsor Name for ONSOLIS
Sponsor Trials
BioDelivery Sciences International 2
University of Florida 1
Hospira, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ONSOLIS
Sponsor Trials
Industry 4
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.